These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Sloan LA J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152 [TBL] [Abstract][Full Text] [Related]
4. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427 [TBL] [Abstract][Full Text] [Related]
5. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". Pugliese G; Penno G; Natali A; Barutta F; Di Paolo S; Reboldi G; Gesualdo L; De Nicola L; Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1127-1150. PubMed ID: 31586514 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous control of glycemic, blood pressure, and lipid significantly reduce the risk of renal progression in diabetes patients. Chang PY; Chien LN; Lin YF; Chiu WT; Chiou HY Eur J Intern Med; 2016 Dec; 36():87-92. PubMed ID: 27707566 [TBL] [Abstract][Full Text] [Related]
7. Achieving glycemic control in patients with type 2 diabetes and renal impairment. Avogaro A; Schernthaner G Acta Diabetol; 2013 Jun; 50(3):283-91. PubMed ID: 23212669 [TBL] [Abstract][Full Text] [Related]
8. [[GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE – HOW TO CHOOSE HYPOGLYCEMIC AGENT]?]. Baretić M; Lang VB Acta Med Croatica; 2016 Dec; 70(4-5):269-74. PubMed ID: 29087153 [TBL] [Abstract][Full Text] [Related]
9. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Haneda M; Morikawa A Nephrol Dial Transplant; 2009 Feb; 24(2):338-41. PubMed ID: 19015168 [No Abstract] [Full Text] [Related]
10. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Tong L; Adler S Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921 [TBL] [Abstract][Full Text] [Related]
11. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice. Abe M; Okada K Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019 [TBL] [Abstract][Full Text] [Related]
12. Narrative review of the effects of antidiabetic drugs on albuminuria. Yaribeygi H; Atkin SL; Katsiki N; Sahebkar A J Cell Physiol; 2019 May; 234(5):5786-5797. PubMed ID: 30367464 [TBL] [Abstract][Full Text] [Related]
13. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Abe M; Okada K; Soma M Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769 [TBL] [Abstract][Full Text] [Related]
15. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024 [TBL] [Abstract][Full Text] [Related]
16. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878 [TBL] [Abstract][Full Text] [Related]
17. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease. Game F Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725 [TBL] [Abstract][Full Text] [Related]
18. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160 [TBL] [Abstract][Full Text] [Related]
19. Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models. Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A J Diabetes Investig; 2021 Jan; 12(1):74-81. PubMed ID: 32506833 [TBL] [Abstract][Full Text] [Related]
20. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Weir MR Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]